Meet DelveInsight in BioEurope '16

  • Home Blog Meet delveinsight in bioeurope 16

Meet DelveInsight in BioEurope '16

Nov 02, 2016

p2-n

Downloads

Article in PDF

Recent Articles
  1. Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights, 2015
  2. Chimerix Submits Dordaviprone NDA for Accelerated Approval in Recurrent H3 K27M-Mutant Diffuse Gl...
  3. FDA Expands SOLIRIS for Pediatric Myasthenia Gravis; vTv’s Cadisegliatin Program Resumes as FDA L...
  4. DNA typos to blame for most Cancer Mutations
  5. Idera’s drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly termin...
pharma-news-for-merck-kalvista-mustang
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Merck’s WINREVAIR Granted FDA Priority Review for Pulmonary Arterial Hypertension; KalVista’s EKTERLY Approved by FDA as First Oral On-Demand Therapy for Hereditary Angioedema; Fujifilm’s FF-10832 Receives FDA Orphan Drug Designation for Biliary Tract Cancer; Mustang Bio’s MB-101 Granted FDA Orphan Drug Designation for Glioblastoma and Astrocytomas; Denali’s Tividenofusp Alfa Accepted for FDA Priority Review for Hunter Syndrome

amniotic-membrane-market-regenerative-healthcare
Articles

How the Amniotic Membrane Market is Transforming Regenerative Healthcare Worldwide

pharma-news-for-sobi-gsk-ultragenyx
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Sobi’s GAMIFANT Approved by FDA as First Treatment for Macrophage Activation Syndrome in Still’s Disease; GSK Cuts RTS,S Malaria Vaccine Price for Children in Endemic Regions to Under $5; Schrödinger’s SGR-1505 Receives FDA Fast Track Designation for Relapsed/Refractory Waldenström Macroglobulinemia; Ultragenyx’s GTX-102 Granted FDA Breakthrough Therapy Designation for Angelman Syndrome; Eli Lilly’s AMYVID Label Updated by FDA to Support Alzheimer’s Disease Diagnosis

BioEurope
Conference
DelveInsight
loader
loader